Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
4/25/25 ALX Oncology (ALXO) Evorpacept for Head and Neck Cancer Subscribers Only Subscribers Only Subscribers Only
4/25/25 Akeso Penpulimab for Nasopharyngeal Cancer Subscribers Only Subscribers Only Subscribers Only
4/24/25 HUYA Bioscience HBI-3000 for Atrial Fibrillation/Flutter Subscribers Only Subscribers Only Subscribers Only
4/21/25 Gilead (GILD) Trodelvy for Triple-Negative Breast Cancer (TNBC) Subscribers Only Subscribers Only Subscribers Only
4/17/25 Eli Lilly (LLY) Orforglipron for Diabetes Mellitus, Type II Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
04/01/2025 Subscribers Only Subscribers Only Company - Divestment/Spinoff
04/05/2025 Subscribers Only Subscribers Only Trial Data - Other
04/24/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
04/24/2025 Subscribers Only Subscribers Only Trial Data - Updated Results
04/25/2025 Subscribers Only Subscribers Only Regulatory - Approval Decision (Europe)